Health Care Select Sector SPDR Fund (XLV)
| Assets | $38.65B |
| Expense Ratio | 0.09% |
| PE Ratio | 29.31 |
| Shares Out | 263.67M |
| Dividend (ttm) | $2.34 |
| Dividend Yield | 1.61% |
| Ex-Dividend Date | Mar 24, 2025 |
| Payout Ratio | 46.95% |
| 1-Year Return | -0.12% |
| Volume | 6,428,094 |
| Open | 147.50 |
| Previous Close | 147.15 |
| Day's Range | 144.35 - 147.52 |
| 52-Week Low | 135.95 |
| 52-Week High | 159.64 |
| Beta | 0.68 |
| Holdings | 62 |
| Inception Date | Dec 16, 1998 |
About XLV
Fund Home PageThe Health Care Select Sector SPDR Fund (XLV) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund tracks health care stocks from within the S&P 500 Index, weighted by market cap. XLV was launched on Dec 16, 1998 and is issued by State Street.
Top 10 Holdings
57.27% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 12.70% |
| UnitedHealth Group Incorporated | UNH | 8.86% |
| Johnson & Johnson | JNJ | 7.33% |
| AbbVie Inc. | ABBV | 6.88% |
| Merck & Co., Inc. | MRK | 4.35% |
| Abbott Laboratories | ABT | 4.11% |
| Thermo Fisher Scientific Inc. | TMO | 3.71% |
| Intuitive Surgical, Inc. | ISRG | 3.38% |
| Amgen Inc. | AMGN | 3.15% |
| Boston Scientific Corporation | BSX | 2.82% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 24, 2025 | $0.56454 | Mar 26, 2025 |
| Dec 23, 2024 | $0.62165 | Dec 26, 2024 |
| Sep 23, 2024 | $0.57723 | Sep 25, 2024 |
| Jun 24, 2024 | $0.57253 | Jun 26, 2024 |
| Mar 18, 2024 | $0.52294 | Mar 21, 2024 |
| Dec 18, 2023 | $0.59772 | Dec 21, 2023 |
News
Energy And Healthcare Stocks Are Big Winners This Year
The Energy Select Sector SPDR ETF is up 8.0% so far this year, far ahead of the broad market, which is nursing a 3.5% year-to-date loss. Healthcare stocks are a strong runner-up performer, rising 6.6%...
Financials, Health Care & BRK/B: Investments to Tackle Volatility
Patrick Mueller notes the market's volatile swings seen through tariffs and policy uncertainty under the Trump administration. That doesn't mean there's no room for investors to enter the market.
Healthcare Stocks Avoid Tariff Damage. There Are Other Problems.
The threat of cuts to Medicaid, plus uncertainty over what the confirmation of Robert F. Kennedy Jr. to lead the U.S. health bureaucracy will mean for the sector, have weighed on the stocks.
Committee Stocks on the Move: Lowe's, TJX Companies, Eli Lilly and the XLV
The Investment Committee discuss some of their stocks that are moving today.
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
Undercovered ETFs: Growth, Income, TIPS, Poland +
The 'Undercovered' Dozen series highlights 12 lesser-known ETFs offering potential investment opportunities for investors. Kurtis Hemmerling shares a bearish take on iShares Russell Top 200 Growth ETF...
Final Trade: FWONK, XLV, MSFT, PEP
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Five ETFs to invest in to hedge against policy uncertainty in 2025
As economic and political uncertainties mount, investors are shifting their strategies toward risk-off investments—assets that provide stability and resilience during volatile periods. With significan...
Financials, Health Care Sectors Leading U.S. Stocks Higher In 2025
The Financial Select Sector SPDR ETF is up 7.8% so far this year. Health care is a close second-place performer with a 6.9% year to date rise.
Healthcare and industrials are two underperforming sectors to watch, says Trivariate's Adam Parker
Trivariate's Adam Parker and Robinhood's Stephanie Guild, join 'Closing Bell' to discuss hyperscalers CapEx numbers and AI spending.
How tariffs could impact pharma and early-stage healthcare investments
Carl Rizzuto, Versant Ventures managing director, joins 'Fast Money' to talk the impact of tariffs on healthcare.
Can Health Care ETFs Aid Your Portfolio?
The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's perfor...
XLV: With Relative Strength In January And Compelling Valuation, Health Care Earnings On Tap
I maintain a buy rating on the Health Care sector, highlighting XLV as the second-best performing S&P 500 sector YTD with broad-based gains. Global fund managers have increased allocations to Health C...
XLV: Buy Diversity And Growth
XLV offers a rare combination of stability and growth potential through its diverse investments in the healthcare sector, justifying a buy rating. The fund's broad exposure across various healthcare s...
The Big 3: META, SLV, XLV
Meta Platforms (META) reports earnings after the closing bell, and @Theotrade's Don Kaufman is bearish on the Mag 7 company. He thinks Meta's significant run higher could end as Don expects its report...
Health care bounce is starting to brew, says Strategas' Chris Verrone
Chris Verrone, Strategas head of technical and macro research, joins 'Closing Bell' to discuss the bullish technical signs he's seeing.
Final Trades: QXO, Stanley Black & Decker, Healthcare and Applovin
The Investment Committee reveals their top stocks to watch. Don't miss their picks!
Healthcare sector poised for rebound in 2025
The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK).
GLP-1 makers could be under pressure in 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk what is next for the obesity drug makers in 2025.
Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year
Healthcare Stocks: 2025 Outlook
I forecast healthcare stocks, especially biopharmaceuticals, to outperform the general averages due to four key investment themes. US healthcare expenditures are expected to grow at an annualized rate...
We're bullish on tech and healthcare going into 2025, says Citizens JPM's Mark Lehmann
Mark Lehmann, head of Citizens JPM, joins CNBC's 'Money Movers' to discuss what sectors he's keeping an eye on going into 2025.
Final Trade: XLV, DEO, OIH & BTC
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
The M&A 'animal spirits' would be a tailwind for the healthcare sector, says JPMorgan's Meera Pandit
Meera Pandit, JPMorgan Asset Management global market strategist, joins 'Closing Bell' to discuss the road ahead for markets and which sectors will be the winners and losers in 2025.